Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

Introduction: The autoantibody-driven disease pemphigus vulgaris (PV) impairs desmosome adhesion in the epidermis. In desmosomes, the pemphigus autoantigens desmoglein 1 (Dsg1) and Dsg3 link adjacent ...

He was instructed to continue the prednisone with an extended-taper dosing schedule in place. The onset and course of pemphigus vulgaris depend on the interaction between predisposing and inducing ...

Issues to be addressed when evaluating a patient for pemphigus include the age of onset, previous clinical symtoms, initial presentation, presence of mucous membrane symptoms and the presence of ...